HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Verona Pharma (NASDAQ:VRNA) and maintained a price target of $36, indicating confidence in the company's future performance.
September 11, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Verona Pharma, maintaining a $36 price target. This suggests confidence in Verona Pharma's future performance and potential stock price appreciation.
The reiteration of a Buy rating and maintenance of a $36 price target by HC Wainwright & Co. indicates a positive outlook on Verona Pharma's stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100